<unk>  is an interleukin-23 antagonist that is FDA approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.   Common adverse reactions include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
Risankizumab
Caplacizumab
Ixekizumab
Tildrakizumab
Mogamulizumab
Idarucizumab
Motavizumab
Tocilizumab